B+
Bull case
25%
Probability
Target price
$1.90
Analysis reference price unavailable
Analysis 2026-05-02 · RankAlpha Sentiment Codex
ENTX
Entera BioFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The constructive case is that EB613 now has a more streamlined Phase 3 path, a single-tablet commercial formulation, and a near-term regulatory feedback checkpoint that could unlock late-2026 study initiation and a clearer 2H 2028 topline path [#PR-2026-03-04].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
As a low-coverage small-cap biotech with only loose same-sector comparators in the packet, ENTX remains vulnerable to sharp repricing if regulatory timing slips, financing needs re-emerge, or investors cannot benchmark the program cleanly against direct peers.
Momentum
98
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.00 · Bull $1.90 · Bear $0.55Analysis 2026-05-02; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-08 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-02 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-08
Investment thesis
As of 2026-09-08
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-08. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $9.00
Why
Momentum98 · Δ7d -0.8
Value41 · Δ7d -0.0
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • As a low-coverage small-cap biotech with only loose same-sector comparators in the packet, ENTX remains vulnerable to sharp repricing if regulatory timing slips, financing needs re-emerge, or investors cannot benchmark the program cleanly against direct peers.
- • EB613 still depends on favorable FDA feedback and timely operational execution before a late-2026 Phase 3 start can become credible [#PR-2026-03-04].
- • The cautious case is that ENTX still looks like a monitoring story: no confirmed post-submission FDA response was found in the checked materials, the company disclosed substantial doubt about continuing as a going concern, and the April private placement added needed cash but also fresh dilution and warrant overhang [#10-K-2026-03-27] [#8-K-2026-04-03].
Catalyst clock
2026-05-03
Pending FDA feedback on the streamlined EB613 Phase 3 amendment
Lead driver: Value · See fundamentals
Momentum
98
9% active weight
Current posture
7d trendFlat
Δ7d
-0.8
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
0
62% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-
Why this grade
Composite grade F. Momentum 98.0 / Value 41.2 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-02. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$1.00
Analysis reference price unavailable
Analysis 2026-05-02 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.55
Analysis reference price unavailable
Analysis 2026-05-02 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$502.11M
Beta
1.86
Shares Out
173.14M
P/E (TTM) · Derived
-11.7
P/S (TTM)
654.58
P/FCF (TTM) · Derived
-12.06
Rev YoY
-100.0%
EPS YoY
+155.6%
Gross Margin
-52.4%
Op Margin
-8729.0%
Net Debt
-$14.39M
Current Ratio
8.98
As of 2026-09-08 • Updated nightlySource: Internal modelMethods & Data